Chemomab Therapeutics (CMMB) Price & Analysis

Compare

262 Followers

CMMB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.87 - $2.55

Previous CloseN/A

Volume58.22K

Average Volume (3M)122.46K

Market Cap

$17.92M

Enterprise Value$14.45M

Total Cash (Recent Filing)$14.27M

Total Debt (Recent Filing)$324.00K

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Nov 07, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding20,764,301

10 Day Avg. Volume115,062

30 Day Avg. Volume122,457

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.81

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-537.12

Enterprise Value/Ebitda-0.98

Forecast

1Y Price Target

$8.50

Price Target Upside794.74% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Study DesignNebokitug's single pivotal Phase 3 study is expected to not require a liver biopsy, using a clinical events-based endpoint, making it less costly and easier to enroll.

Regulatory ApprovalChemomab announced positive feedback from the FDA following its End-of-Phase 2 and Type C meetings to support advancing nebokitug into Phase 3 development for primary sclerosing cholangitis.

Strategic PartnershipsChemomab is in active strategic partnering discussions to advance the program into Phase 3, which is expected to bring the asset forward significantly.

Bears Say

Biopsy RequirementsAvoiding a biopsy endpoint was a key objective of Chemomab's regulatory interactions. Biopsy endpoints complicate enrollment and add considerable additional cost.

Enrollment ChallengesNo liver biopsies. This is a critical aspect of the study. Liver biopsy is highly invasive, costly, and complicate enrollment.

Chemomab Therapeutics News

Chemomab Therapeutics management to meet with Maxim

Meeting to be held on August 7-8 hosted by Maxim. Published first on TheFly – the ultimate source...

13d ago

CMMB

Chemomab Therapeutics Enters Sales Agreement with LifeSci Capital

The latest announcement is out from Chemomab Therapeutics ( ($CMMB) ). On July 25, 2025, Chemomab Therapeutics Ltd....

19d ago

CMMB

Chemomab Therapeutics Announces Key Decisions from Annual Shareholders Meeting

Chemomab Therapeutics ( ($CMMB) ) has provided an announcement. On July 1, 2025, Chemomab Therapeutics held its annual...

1M ago

CMMB

Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug

Chemomab Therapeutics (CMMB) announced that data from the company’s Phase 2 SPRING trial of nebokitug in patients with...

1M ago

CMMB

Chemomab obtained feedback from two recent FDA meetings on nebokitug

Chemomab Therapeutics (CMMB) reported that it has obtained confirmation from the FDA on two significant development milestones as...

2M ago

CMMB

Chemomab announces nebokitug awarded new patent protection in China, Russia

Chemomab Therapeutics (CMMB) announced that its lead product nebokitug has been awarded new patent protections in China and...

2M ago

CMMB

Chemomab Therapeutics Announces Annual General Meeting for July 2025

Chemomab Therapeutics ( ($CMMB) ) just unveiled an announcement. On May 27, 2025, Chemomab Therapeutics announced its upcoming...

3M ago

CMMB

Chemomab Therapeutics: Promising Prospects with Streamlined Path to Approval and Strategic Advancements

Chemomab Therapeutics (CMMB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

3M ago

CMMB

Chemomab Therapeutics Advances Nebokitug for PSC Treatment

Chemomab Therapeutics Ltd. ( ($CMMB) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

CMMB

Chemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer

Oppenheimer analyst Jeff Jones lowered the firm’s price target on Chemomab Therapeutics (CMMB) to $10 from $11 and...

3M ago

CMMB

Chemomab Therapeutics Advances Nebokitug Towards Phase 3 After Positive Trial Results

The latest update is out from Chemomab Therapeutics ( ($CMMB) ). On May 15, 2025, Chemomab Therapeutics announced...

3M ago

CMMB

Chemomab Therapeutics reports Q1 EPS $0.007 vs $0.014 last year

“In the first quarter of 2025 Chemomab continued to successfully deliver on its commitments, achieving two major milestones...

3M ago

CMMB

Chemomab Therapeutics: Promising Phase 2 Data and Attractive Entry Point Justify Buy Rating

Maxim Group analyst Jason McCarthy maintained a Buy rating on Chemomab Therapeutics (CMMB – Research Report) today and...

3M ago

CMMB

Chemomab Therapeutics announces presentation of Phase 2 data of CM-101

Chemomab Therapeutics (CMMB) announced that data from the company’s Phase 2 SPRING trial of nebokitug, CM-101, in primary...

3M ago

CMMB

CMMB FAQ

What was Chemomab Therapeutics’s price range in the past 12 months?

Chemomab Therapeutics lowest stock price was $0.87 and its highest was $2.55 in the past 12 months.

What is Chemomab Therapeutics’s market cap?

Chemomab Therapeutics’s market cap is $17.92M.

When is Chemomab Therapeutics’s upcoming earnings report date?

Chemomab Therapeutics’s upcoming earnings report date is Nov 07, 2025 which is in 86 days.

How were Chemomab Therapeutics’s earnings last quarter?

Currently, no data Available

Is Chemomab Therapeutics overvalued?

According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Chemomab Therapeutics pay dividends?

Chemomab Therapeutics does not currently pay dividends.

What is Chemomab Therapeutics’s EPS estimate?

Chemomab Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Chemomab Therapeutics have?

Chemomab Therapeutics has 20,764,301 shares outstanding.

What happened to Chemomab Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Chemomab Therapeutics?

Currently, no hedge funds are holding shares in CMMB

Chemomab Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-112.99%

Trailing 12-Months

Asset Growth

-28.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Chemomab Therapeutics (CMMB) Earnings & Revenues

Historic Earnings Reports

CMMB Stock 12 Month Forecast

Average Price Target

$8.50

▲(794.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,2.0153846153846153,2.680769230769231,3.3461538461538467,4.011538461538462,4.676923076923078,5.342307692307693,6.007692307692308,6.673076923076923,7.338461538461539,8.003846153846155,8.66923076923077,9.334615384615386,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.9000000000000001,2.45,3,3.5500000000000003,4.1,4.65,5.200000000000001,5.75,6.300000000000001,6.85,7.4,7.950000000000001,{"y":8.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.7846153846153847,2.2192307692307693,2.653846153846154,3.0884615384615386,3.5230769230769234,3.957692307692308,4.392307692307693,4.826923076923077,5.261538461538462,5.696153846153846,6.13076923076923,6.565384615384616,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.73,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >